CRISPR Therapeutics AG
http://www.crisprtx.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From CRISPR Therapeutics AG
Beam Picks Crowded AAT Field To Prove Its In Vivo Gene Editing
With its first US study for a base-edited CAR-T therapy now back on track, Beam Therapeutics is gearing up to begin studies of its first in vivo candidate, BEAM-302, next year in AAT.
Gene Therapy: What To Expect Now And In The Future
The US FDA could approve as many new gene therapies in 2023 as it has in the previous five years. Development in the field has rapidly accelerated, but still faces hurdles.
Price Negotiation And Sickle Cell ‘Cures’: Dueling Biopharma Headlines This Fall
The two sides of the US public’s perceptions of the biopharma industry are likely to dominate the headlines this fall. Will the industry emerge defined by innovation and hope for better health? Or by massive profits protected by litigation?
Keeping Track: Pfizer And J&J’s Dueling Myeloma Bispecifics; Regeneron And Ipsen Nab Priority Vouchers
Shared REMS, diverse confirmatory trials and manufacturing delays are among the highlights in the latest US FDA drug approval news from the Pink Sheet’s US FDA Performance Tracker.
Company Information
- Industry
- Pharmaceuticals
-
Pharmaceuticals
- Drug Delivery
-
Biotechnology
- Gene Therapy, Cell Therapy
- Large Molecule
-
Drug Discovery Tools
- Genomics-Proteomics
- Other Names / Subsidiaries
-
- Casebia Therapeutics
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice